Grey Matters Closes First Tranche of $600,000 of its Equity and Convertible Debenture Private Placement

22 hours ago 3

Article content

The Company paid cash finder’s fees of CAD $14,800 and issued 2,000 finders warrants pertaining to the First Tranche of the Offering.

Article content

The Company will use the proceeds of the Offering to advance its Alzheimer’s Disease program towards the opening of U.S. brain-specific neuroimaging clinic, general and administrative expenses, and for working capital purposes.

Article content

The Offering will remain open and the Company expects to close additional tranches on or before September 30, 2026.

Article content

The Company also announces a grant of 100,000 restricted share units pursuant to its RSU plan (each, an “RSU”) to certain consultants of the Company. Each RSU entitles the recipient to receive one Common Share of the Company or a cash payment equal to the equivalent of one Common Share of the Company on vesting. The vesting dates of the RSUs includes; 37,500 vesting on the date of grant, 12,500 vesting on October 17 2026, 12,500 vesting on January 17, 2027, 12,500 vesting on April 17, 2027 and 25,000 vesting on September 9, 2027.

Article content

The securities issued and issuable, described in this and the previous news release from August 20, 2026, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

Article content

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration.

Article content

For more information please contact:

Article content

Christopher J. Moreau
CEO
Grey Matters Health Inc.
604.398.4175 Ext 701

Article content

About Grey Matters

Article content

Grey Matters is a Canadian healthcare company focused on the provision of brain dedicated PET scanning services through a planned network of new neuroimaging clinics in the U.S. for the early-stage detection of Alzheimer’s Disease and other forms of neurodegenerative diseases, including frontotemporal dementia, Parkinson’s, and Lewy body dementia, and will additionally offer other select neuro-oncology imaging applications too.

Article content

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Article content

CAUTIONARY DISCLAIMER STATEMENT: This news release contains forward-looking statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Article content